Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain.

导出 LinkOut

翻译打印收藏纠错

作者： James R,Burke ^[1] ; Lihong,Cheng ^[2] ; Kathleen M,Gillooly ^[2] ; Joann,Strnad ^[2] ; Adriana,Zupa-Fernandez ^[2] ; Ian M,Catlett ^[3] ; Yifan,Zhang ^[2] ; Elizabeth M,Heimrich ^[2] ; Kim W,McIntyre ^[2] ; Mark D,Cunningham ^[4] ; Julie A,Carman ^[4] ; Xiadi,Zhou ^[2] ; Dana,Banas ^[4] ; Charu,Chaudhry ^[5] ; Sha,Li ^[5] ; Celia,D'Arienzo ^[6] ; Anjaneya,Chimalakonda ^[6] ; XiaoXia,Yang ^[2] ; Jenny H,Xie ^[2] ; Jian,Pang ^[2] ; Qihong,Zhao ^[2] ; Shawn M,Rose ^[3] ; Jinwen,Huang ^[2] ; Ryan M,Moslin ^[7] ; Stephen T,Wrobleski ^[7] ; David S,Weinstein ^[7] ; Luisa M,Salter-Cid ^[2]

作者单位： Immunosciences Discovery Biology, Bristol-Myers Squibb Research and Development, Princeton, NJ 08543, USA. james.burke@bms.com. ^[1] Immunosciences Discovery Biology, Bristol-Myers Squibb Research and Development, Princeton, NJ 08543, USA. ^[2] Innovative Medicines Development, Bristol-Myers Squibb Research and Development, Princeton, NJ 08543, USA. ^[3] Translational Medicine, Bristol-Myers Squibb Research and Development, Princeton, NJ 08543, USA. ^[4] Leads Discovery and Optimization, Bristol-Myers Squibb Research and Development, Princeton, NJ 08543, USA. ^[5] Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, Princeton, NJ 08543, USA. ^[6] Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research and Development, Princeton, NJ 08543, USA. ^[7]